Cetirizine in horses: Pharmacokinetics and effect of ivermectin pretreatment

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 3, 2007, Pages 194-200

  Olsen L ^a   Ingvast Larsson, C ^a   Bondesson, U ^b,c   Brostrom H ^a   Tjalve H ^a   Larsson, P ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZIN; CETIRIZINE; GLYCOPROTEIN P INHIBITOR; IVERMECTIN; NOROMECTIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CELL MEMBRANE; DRUG EFFICACY; DRUG INHIBITION; DRUG URINE LEVEL; FEMALE; HORSE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EXCRETION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARASITIC AGENTS; AREA UNDER CURVE; CETIRIZINE; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HORSES; IVERMECTIN; MALE;

EQUIDAE;

EID: 34247640072     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00850.x     Document Type: Article

References (32)

1. Benedetti, M.S., Plisnier, M., Kaise, J., Maier, L., Baltes, E., Arendt, C. McCracken, N. (2001) Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. European Journal of Clinical Pharmacology, 57, 571 582.
2. Bree, F., Thiahult, L., Gautiers, G., Benedetti, M.S., Baltes, E., Rihoux, J.-P. Tillement, J.-P. (2002) Blood distribution of levocetirizine, a new non-sedating histamine H1-receptor antagonist, in humans. Fundamental and Clinical Pharmacology, 16, 471 478.
3. Chen, C., Hanson, E., Watson, J.W. Lee, J.S. (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metabolism and Disposition, 31, 312 318.
4. Curran, M.P., Scott, L.J. Perry, C.M. (2004) Cetirizine: a review of its use in allergic disorders. Drugs, 64, 523 561.
5. Devalia, J.L., De Vos, C., Hanotte, F. Baltes, E. (2001) A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy, 56, 50 57.
6. Didier, A. Loor, F. (1996) The abamectin derivate ivermectin is a potent P-glycoprotein inhibitor. Anti-Cancer Drugs, 7, 745 751.
7. Foster, A.P., McKelvie, J. Cunningham, F.M. (1998) Inhibition of antigen-induced cutaneous responses of ponies with insect hypersensibility by histamine-1 receptor antagonist chlorphentamine. The Veterinary Record, 143, 189 193.
8. Gillard, M., Van Der Perren, C., Moguilevsky, N., Massingham, R. Chatelain, P. (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Molecular Pharmacology, 61, 391 399.
9. Gillard, M., Strolin Benedetti, M., Chatelain, P. Baltes, E. (2005) Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflammation Research, 54, 367 369.
10. Gupta, A., Hammarlund-Udenaes, M., Chatelain, P., Massingham, R. Jonsson, E.N. (2006) Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. Biopharmaceutics and Drug Disposition, 27, 291 297.
11. Laffont, C.M., Toutain, P.L., Alvinerie, M. Bousquet-Melou, A. (2002) Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metabolism and Disposition, 30, 626 630.
12. Matzke, G.R., Yeh, J., Awni, W.M., Halstenson, C.E. Chung, M. (1987) Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Annals of Allergy, 59, 25 30.
13. Morrow, A., Quinn, P.J. Baker, K.P. (1986) Dermal reactivity to histamine, serotonin and bradykinin in relation to allergic skin reactions of the horse. Journal of Veterinary Pharmacology and Therapeutics, 9, 40 48.
14. Olsén, L., Ingvast-Larsson, C., Larsson, P., Broström, H., Bondesson, U., Sundqvist, M. Tjälve, H. (2006) Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. Journal of Veterinary Pharmacology and Therapeutics, 29, 129 135.
15. Orzechowski, R.F., Currie, D.S. Valancius, C.A. (2005) Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. European Journal of Pharmacology, 506, 257 264.
16. Pagliara, A., Testa, B., Carrupt, P.-A., Jolliet, P., Morin, C., Morin, D., Urien, S., Tillement, J.-P. Rihoux, J.-P. (1998) Molecular properties and pharmacokinetic behaviour of cetirizine, a zwitterionic H1-receptor antagonist. Journal of Medicinal Chemistry, 41, 853 863.
17. Pérez, R., Cabezas, I., Godoy, C., Rubilar, L., Munoz, L., Arboix, M., Castells, G. Alvinerie, M. (2002) Pharmacokinetics of doramectin and ivermectin after oral administration in horses. Veterinary Journal, 163, 161 167.
18. Peytavin, G., Gautran, C., Otoul, C., Cremieux, A.C., Moulaert, B., Delatour, F., Melac, M., Benedetti, M.S. Farinotti, R. (2005) Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. European Journal of Clinical Pharmacology, 61, 267 273.
19. Polli, J.W., Baugman, T.M., Humphreys, J.E., Jordan, K.H., Mote, A.L., Salisbury, J.A., Tippin, T.K. Serabjit-Singh, C.J. (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. Journal of Pharmaceutical Sciences, 92, 2082 2089.
20. Rosenkrantz, W.S. (1995) Systemic/topical therapy. The Veterinary Clinics of North America Equine Practice, 11, 127 146.
21. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C. Riele, H.P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491 502.
22. Simons, F. (2001) Prevention of acute urticaria in young children with atopic dermatitis. Journal of Allergy and Clinical Immunology, 107, 703 706.
23. Snyder, S.H. Snowman, A.M. (1987) Receptor effects of cetirizine. Annals of Allergy, 59, 4 8.
24. Tashiro, M., Sakurada, Y., Iwabuchi, K., Mochizuki, H., Kato, M., Aoki, M., Funaki, Y., Itoh, M., Iwata, R., Wong, D.F. Yanai, K. (2004) Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. Journal of Clinical Pharmacology, 44, 890 900.
25. Theunissen, E.L., Vermeeren, A., van Oers, A.C., van Maris, I. Ramaekers, J.G. (2004) A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clinical and Experimental Allergy, 34, 250 258.
26. Theunissen, E.L., Vermeeren, A. Ramaekers, J.G. (2006) Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. British Journal of Clinical Pharmacology, 61, 79 86.
27. Törneke, K., Ingvast-Larsson, C., Pettersson, K., Bergvall, K., Hedeland, M., Bondesson, U. Broström, H. (2003) Pharmacokinetics and pharmacodynamics of clemastine in healthy horses. Journal of Veterinary Pharmacology and Therapeutics, 26, 151 157.
28. Toutain, P.L. Bousquet-Mélou, A. (2004) Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics, 27, 455 466.
29. Tydén, E., Olsén, L., Tallkvist, J., Larsson, P. Tjälve, H. (2004) CYP3A in horse intestines. Toxicology and Applied Pharmacology, 201, 112 119.
30. Tydén, E., Tjälve, H., Tallkvist, J. Larsson P. (2006) P-glycoprotein in the intestine, liver and kidney of the horse (abstract). Journal of Veterinary Pharmacology and Therapeutics, 26 (Suppl. 1 120 121.
31. Wood, S.G., John, B.A., Chasseaud, L.F., Yeh, J. Chung, M. (1987) The metabolism and pharmacokinetics of 14C-cetirizine in humans. Annals of Allergy, 59, 31 34.
32. Zuberbier, T. Henz, B.M. (1999) Use of cetirizine in dermatologic disorders. Annals of Allergy, Asthma and Immunology, 83, 476 480.